BENAZEPRIL HYDROCHLORIDE- benazepril hydrochloride tablet, film coated

国家: 美国

语言: 英文

来源: NLM (National Library of Medicine)

有效成分:

BENAZEPRIL HYDROCHLORIDE (UNII: N1SN99T69T) (BENAZEPRILAT - UNII:JRM708L703)

可用日期:

Mylan Institutional Inc.

INN（国际名称）:

BENAZEPRIL HYDROCHLORIDE

组成:

BENAZEPRIL HYDROCHLORIDE 10 mg

给药途径:

ORAL

处方类型:

PRESCRIPTION DRUG

疗效迹象:

Benazepril hydrochloride tablets are indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including the class to which this drug principally belongs. Control of high blood pressure should be part of comprehensive cardiovascular risk management, including, as appropriate, lipid control, diabetes management, antithrombotic therapy, smoking cessation, exercise, and limited sodium intake. Many patients will require more than one drug to achieve blood pressure goals. For specific advice on goals and management, see published guidelines, such as those of the National High Blood Pressure Education Program’s Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC). Numerous antihypertensive drugs, from

產品總結:

Benazepril Hydrochloride Tablets, USP are available containing 10 mg or 20 mg of benazepril hydrochloride, USP. The 10 mg tablets are white, film-coated, round, unscored tablets debossed with M on one side of the tablet and 443 on the other side. They are available as follows: NDC 51079-145-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). The 20 mg tablets are white, film-coated, round, unscored tablets debossed with M over 444 on one side of the tablet and blank on the other side. They are available as follows: NDC 51079-146-20 – Unit dose blister packages of 100 (10 cards of 10 tablets each). Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.] Protect from moisture.

授权状态:

Abbreviated New Drug Application

产品特点

BENAZEPRIL HYDROCHLORIDE- BENAZEPRIL HYDROCHLORIDE TABLET, FILM COATED
MYLAN INSTITUTIONAL INC.
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
THESE HIGHLIGHTS DO NOT INCLUDE ALL THE INFORMATION NEEDED TO USE
BENAZEPRIL HYDROCHLORIDE TABLETS
SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING INFORMATION FOR
BENAZEPRIL HYDROCHLORIDE TABLETS.
BENAZEPRIL HYDROCHLORIDE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 1991
WARNING: FETAL TOXICITY
_SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING._
WHEN PREGNANCY IS DETECTED, DISCONTINUE BENAZEPRIL HYDROCHLORIDE
TABLETS AS SOON AS POSSIBLE. ( 5.1)
DRUGS THAT ACT DIRECTLY ON THE RENIN-ANGIOTENSIN SYSTEM CAN CAUSE
INJURY AND DEATH TO THE DEVELOPING
FETUS. ( 5.1)
INDICATIONS AND USAGE
Benazepril hydrochloride tablets are an angiotensin-converting enzyme
(ACE) inhibitor indicated for the treatment of
hypertension, to lower blood pressure. Lowering blood pressure reduces
the risk of fatal and nonfatal cardiovascular
events, primarily strokes and myocardial infarctions. ( 1)
DOSAGE AND ADMINISTRATION
Adult Patients: Initiate with 10 mg once daily (or 5 mg if patient is
on diuretic). Titrate to 40 mg daily based on blood
pressure response. ( 2.1)
Pediatric patients age 6 years and above with glomerular filtration
rate (GFR) > 30 mL/min/1.73 m
: Initiate with 0.2
mg/kg once daily. Maximum dose is 0.6 mg/kg once daily.
Renal Impairment: Initiate with 5 mg once daily in patients with GFR <
30 mL/min/1.73 m
(serum creatinine > 3
mg/dL). ( 2.2)
DOSAGE FORMS AND STRENGTHS
Tablets: 5 mg, 10 mg, 20 mg, 40 mg
CONTRAINDICATIONS
Angioedema or history of hereditary or idiopathic angioedema ( 4)
Hypersensitivity ( 4)
Coadministration with aliskiren in patients with diabetes ( 4)
WARNINGS AND PRECAUTIONS
Angioedema: Discontinue benazepril hydrochloride tablets and treat
appropriately. ( 5.2)
Monitor renal function periodically. ( 5.3)
Monitor blood pressure after initiation. ( 5.4)
Hyperkalemia: Monitor serum potassium periodically. ( 5.5)
Hepatic toxicity: Monitor for jaundice or signs